Friday April 26, 2024 | Last Update: April 26, 2024 EDT
GlaxoSmithKline plc (GSK) has announced in a press release that it will be acquiring Bristol-Myers Squibb’s late-stage HIV R&D assets and its portfolio of preclinical and discovery stage HIV research assets. The HIV assets complement GSK’s global HIV business ViiV Healthcare’s existing portfolio.
Read more >>
Just In
Most Read
1
2
3
4
5